Will HAE Stock Gain Following Sell-Off of Whole Blood Assets to GVS?

Haemonetics Corporation (HAE) recently entered into a definitive agreement with GVS, S.p.A ("GVS") to sell its whole blood assets. Haemonetics intends to use the proceeds from this transaction for general corporate purposes and additional investments in growth initiatives.The transaction comprises a total cash consideration of up to $67.1 million, which includes $44.6 million in upfront and up to $22.5 million in contingent earn-outs over the next four years. HAE’s Likely Stock Trend Following the NewsSubse ...